Investments Ab Karolinska D... Net Worth

The estimated Net Worth of Investments Ab Karolinska D... is at least 21.3 百万$ dollars as of 7 July 2020. Investments D owns over 241,703 units of Aprea Therapeutics stock worth over 6,416,127$ and over the last 5 years Investments sold APRE stock worth over 14,930,464$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Investments D APRE stock SEC Form 4 insiders trading

Investments has made over 2 trades of the Aprea Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Investments sold 241,703 units of APRE stock worth 8,350,839$ on 7 July 2020.

The largest trade Investments's ever made was selling 241,703 units of Aprea Therapeutics stock on 7 July 2020 worth over 8,350,839$. On average, Investments trades about 150,750 units every 28 days since 2019. As of 7 July 2020 Investments still owns at least 1,992,586 units of Aprea Therapeutics stock.

You can see the complete history of Investments D stock trades at the bottom of the page.

Insiders trading at Aprea Therapeutics

Over the last 5 years, insiders at Aprea Therapeutics have traded over 63,126,246$ worth of Aprea Therapeutics stock and bought 2,073,560 units worth 29,606,912$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Vantage I, L.P.Versant Vant...、John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of 420,918$. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth 7,363$.

What does Aprea Therapeutics do?

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Complete history of Investments D stock trades at Aprea Therapeutics

Aprea Therapeutics executives and stock owners

Aprea Therapeutics executives and other stock owners filed with the SEC include:

• Christian Schade,
  Chairman of the Board, President, Chief Executive Officer
• Scott Coiante,
  Chief Financial Officer, Senior Vice President, Secretary
• Eyal Attar,
  Senior Vice President, Chief Medical Officer
• Christian S. Schade,
  Pres, CEO & Chairman
• Dr. Eyal C. Attar M.D.,
  Sr. VP & Chief Medical Officer
• Scott M. Coiante,
  Sr. VP, Company Sec. & CFO
• John Henneman,
  Lead Independent Director
• Bernd Seizinger,
  Independent Director
• Guido Magni,
  Independent Director
• Johan Christenson,
  Independent Director
• Dr. Oren Gilad Ph.D.,
  Co-Founder, Pres & Director
• Richard Peters,
  Director
• Fouad Namouni,
  Director
• Michael Kelly,
  Director
• Gregory Wessels,
  Chief Commercial Officer
• Gregory Korbel,
  Vice President - Business Development
• Lars Abrahmsen,
  Senior Vice President, Chief Scientific Officer
• Andrea Epstein,
  Controller
• Dr. Michel Afargan Ph.D.,
  Head of Pharmacology Devel.
• Hank Breslin,
  Head of Medicinal Chemistry
• Dr. Rifat Pamukcu M.D.,
  Chief Medical Advisor & Director
• Dr. Dansu Li Ph.D.,
  Head of Technology
• Dr. Lars B. Abrahmsen,
  Sr. VP & Chief Scientific Officer
• Dr. Gregory A. Korbel Ph.D.,
  Sr. VP & Chief Bus. Officer
• Ventures Iv, L.P.5 Am Co In...,
  
• Marc Duey,
  Director
• Michael Grissinger,
  Director
• Rifat Pamukcu,
  Director
• Ventures Iv, L.P.5 Am Co In...,
  
• V Luxco S.A R.L.Versant Ven...,
  
• Oren Gilad,
  President, CEO
• Investments Ab Karolinska D...,
  
• Scott M Rocklage,
  Director
• V Luxco S.A R.L.Versant Ven...,
  
• Vantage I, L.P.Versant Vant...,
  
• Group, Llc Green Jeremy Red...,
  
• Vii, L.P.Health Cap Vii Gp ...,
  
• Jonathan Hepple,
  
• John P. Hamill,
  SrVP/CFO/Prin Fin & Acct Ofcr
• Gabriela Gruia,
  Director
• Jean Pierre Bizzari,
  Director
• Nadeem Q. Mirza,
  Chief Medical Officer